Advertisement

Journal of Gastroenterology

, Volume 46, Issue 6, pp 799–808 | Cite as

Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy

  • Yuko Nagaoki
  • Hiroshi AikataEmail author
  • Daisuke Miyaki
  • Eisuke Murakami
  • Yoshimasa Hashimoto
  • Yoshio Katamura
  • Takahiro Azakami
  • Tomokazu Kawaoka
  • Shintaro Takaki
  • Akira Hiramatsu
  • Koji Waki
  • Michio Imamura
  • Yoshiiku Kawakami
  • Shoichi Takahashi
  • Kazuaki Chayama
Original Article—Liver, Pancreas, and Biliary Tract

Abstract

Background

We evaluated the clinical features and the prognostic factors of hepatocellular carcinoma (HCC) developed after hepatitis C virus (HCV) eradication with interferon (IFN) therapy.

Methods

Forty-one consecutive patients who developed HCC after HCV eradication with IFN therapy were enrolled. Clinical features were reviewed, and overall survival and associated factors were analyzed. The recurrence rate in 26 patients receiving radical therapy was also analyzed.

Results

Twenty patients developed HCC within 5 years after the end of IFN therapy, 9 patients developed the disease from 5 to 10 years after the end of the therapy, 9 patients developed the disease from 10 to 15 years after the end of the therapy, and 3 patients developed the disease from 15 years after the end of the therapy. Multivariate analysis of independent variables for the development of HCC within 5 years identified age >55 years at HCV eradication (P = 0.007) and heavy alcohol intake (P = 0.009). The 5-year survival rate was 64%. On multivariate analysis of overall survival for the 41 patients, the only risk factor with prognostic influence was radical therapy (P = 0.010), which was associated with a cumulative 5-year survival rate of 91%. The only independent factor for the receipt of radical therapy was regular surveillance for HCC (P = 0.004). Among patients receiving radical therapy, the 3- and 5-year recurrence rates were 18 and 18%, respectively.

Conclusion

We found that, despite HCV eradication, patients with the risk factors of high age at HCV eradication and heavy alcohol intake might be at heightened risk for the development of HCC within 5 years after HCV eradication. In contrast, risk factors for the development of HCC more than 10 years after HCV eradication were uncertain. These findings indicate the need for long-term surveillance for HCC after HCV eradication.

Keywords

Hepatocellular carcinoma Hepatitis C virus Interferon Sustained virological response Surveillance 

References

  1. 1.
    Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328:1797–801.PubMedCrossRefGoogle Scholar
  2. 2.
    Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 1995;21:650–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Shiratori Y, Shiina S, Imamura M, Kato N, Kanai F, Okudaira T, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C- viral infection in Japan. Hepatology. 1995;22:1027–33.PubMedCrossRefGoogle Scholar
  4. 4.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003;362:1907–17.PubMedCrossRefGoogle Scholar
  5. 5.
    Ikeda K, Saitoh S, Koida I, Arase Y, Tsubota A, Chayama K, et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology. 1993;18:47–53.PubMedCrossRefGoogle Scholar
  6. 6.
    Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463–72.PubMedCrossRefGoogle Scholar
  7. 7.
    Oka H, Kurioka N, Kim K, Kanno T, Kuroki T, Mizoguchi Y, et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 1990;12:680–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Bisceglie AD, Peters M, et al. Treatment of chronic hepatitis non-A, non-B hepatitis with recombinant human alpha interferon. N Engl J Med. 1986;315:1575–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Kasahara A, Hayashi N, Mochizuki K, Takayanagi M, Yoshioka K, Kakumu S, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology. 1998;27:1394–402.PubMedCrossRefGoogle Scholar
  10. 10.
    Imai Y, Kawata S, Tamura S, Yabuuchi I, Noda S, Inada M, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998;129:94–9.PubMedGoogle Scholar
  11. 11.
    Ikeda K, Saitoh S, Arase Y, Chayama K, Suzuki Y, Kobayashi M, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124–30.PubMedCrossRefGoogle Scholar
  12. 12.
    Poynard T, Moussalli J, Ratziu V, Regimbeau C, Opolon P. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis. 1999;3:869–81.PubMedCrossRefGoogle Scholar
  13. 13.
    Yoshida H, Shiratori Y, Moriyama M, Arakawa Y, Ide T, Sata M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174–81.PubMedGoogle Scholar
  14. 14.
    Yoshida H, Tateishi R, Arakawa Y, Sata M, Fujiyama S, Nishiguchi S, et al. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Gut. 2004;53:425–30.PubMedCrossRefGoogle Scholar
  15. 15.
    Coverdale SA, Khan MH, Byth K, Lin R, Weltman M, George J, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year follow-up study. Am J Gastroenterol. 2004;99:636–44.PubMedCrossRefGoogle Scholar
  16. 16.
    Okanoue T, Itoh Y, Minami M, Sakamoto S, Yasui K, Sakamoto M, et al. Interferon therapy lowers the rate of progression to hepatocellular carcinoma on chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. J Hepatol. 1999;30:653–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 2000;87:741–9.PubMedCrossRefGoogle Scholar
  18. 18.
    Kim SR, Matsuoka T, Maekawa Y, Yano Y, Imoto S, Kudo M, et al. Development of multicentric hepatocellular carcinoma after completion of interferon therapy. J Gastroenterol. 2002;37:663–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Shindo M, Hamada K, Oda Y, Okuno T. Long-term follow-up study of sustained biochemical responders with interferon therapy. Hepatology. 2001;33:1299–302.PubMedCrossRefGoogle Scholar
  20. 20.
    Ikeda M, Fujiyama S, Tanaka M, Sata M, Ide T, Yatsuhashi H, et al. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. J Gastroenterol. 2005;40:148–56.PubMedCrossRefGoogle Scholar
  21. 21.
    Toyoda H, Kumada T, Tokuda A, Sano K, Kubota K, Makuuchi M. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J Viral Hepat. 2000;7:414–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Makiyama A, Itoh Y, Kasahara A, Imai Y, Kawata S, Yoshioka K, et al. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer. 2004;101:1616–22.PubMedCrossRefGoogle Scholar
  23. 23.
    Yoshida H, Arakawa Y, Sata M, et al. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology. 2002;123:483–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Enokimura N, Shiraki K, Kawakita T, Saitou Y, Inoue H, Okano H, et al. Hepatocellular carcinoma development in sustained viral responders to interferon therapy in patients with chronic hepatitis C. Anticancer Res. 2003;23:593–6.PubMedGoogle Scholar
  25. 25.
    Mashitani T, Yoshiji H, Yamazaki M, Ikenaka Y, Noguchi R, Ishikawa M, et al. Development of hepatocellular carcinoma in a patient 13 years after sustained virological response to interferon against chronic hepatitis C: a case report. Cases J. 2009;2(1):18.PubMedGoogle Scholar
  26. 26.
    Miki D, Aikata H, Uka K, Saneto H, Kawaoka T, Azakami T, et al. Clinicopathological features of elderly patients with hepatitis C virus-related hepatocellular carcinoma. J Gastroenterol. 2008;43(7):550–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Saneto H, Kobayashi M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, et al. Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma: differences between young and elderly patients. J Gastroenterol. 2008;43(12):975–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Chiba T, Matsuzaki Y, Abei M, Shoda J, Aikawa T, Tanaka N, et al. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J Gastroenterol. 1996;31:552–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Degos F, Christidis C, Ganne-Carrie N, Farmachidi JP, Degott C, Guettier C, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut. 2000;47:131–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer. 2000;89(1):53–9.Google Scholar
  31. 31.
    Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142:105–14.PubMedGoogle Scholar
  32. 32.
    Adami HO, Chow WH, Nyren O, Berne C, Linet MS, Ekbom A, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst. 1996;88:1472–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Braga C, La Vecchia C, Negri E, Franceschi S. Attributable risks for hepatocellular carcinoma in Northern Italy. Eur J Cancer. 1997;83:1820–6.Google Scholar
  34. 34.
    La Vecchia C, Negri E, Decali A, Franceschi S. Diabetes mellitus and the risk of primary liver cancer. Int J Cancer. 1997;73:204–7.PubMedCrossRefGoogle Scholar
  35. 35.
    Hassan MM, Hwang LY, Hatten CJ, Swaim M, Li D, Abbruzzese JL, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36:1206–13.PubMedCrossRefGoogle Scholar
  36. 36.
    El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126:460–8.PubMedCrossRefGoogle Scholar
  37. 37.
    Kiyosawa K, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Gad A, et al. Hepatocellular carcinoma: recent trends in Japan. Gastroenterology. 2004;127:S17–26.PubMedCrossRefGoogle Scholar
  38. 38.
    Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127:S35–50.PubMedCrossRefGoogle Scholar
  39. 39.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003;348:1625–38.PubMedCrossRefGoogle Scholar
  40. 40.
    Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM, et al. Obesity and hepatocellular carcinoma. Gastroenterology. 2004;127:S97–103.PubMedCrossRefGoogle Scholar
  41. 41.
    Ohki T, Tateishi R, Sato T, Masuzaki R, Imamura J, Goto T, et al. Obesity is an independent risk factor for hepatocellular carcinoma development in chronic hepatitis C patients. Clin Gastroenterol Hepatol. 2008;6:459–64.PubMedCrossRefGoogle Scholar
  42. 42.
    Waranabe S, Yaginuma R, Ikejima K, Miyazaki A. Liver diseases and metabolic syndrome. J Gastroenterol. 2008;43:509–18.CrossRefGoogle Scholar
  43. 43.
    Ikeda K, Saitoh S, Tsubota A, Arase Y, Chayama K, Kumada H, Tsurumaru M, et al. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer. 1993;71:19–25.PubMedCrossRefGoogle Scholar
  44. 44.
    Grazi GL, Ercoloani G, Pierangeli F, Del Gaudio M, Cescon M, Cavallari A, et al. Improved results of liver resection for hepatocellular carcinoma on cirrhosis give the procedure added value. Ann Surg. 2001;234:71–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Lise M, Bacchetti S, Pian PD, Nitti D, Pilati PL, Pigato P. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. Cancer. 1998;82:1028–36.PubMedCrossRefGoogle Scholar
  46. 46.
    Izumi R, Shimizu K, Il T, Yagi M, Matsui O, Nonomura A, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 1994;106:720–7.PubMedGoogle Scholar
  47. 47.
    Ercolani G, Grazi GL, Ravaioli M, Gaudio MD, Gardini A, Cescon M, et al. Liver resection for hepatocellular carcinoma on cirrhosis: univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg. 2003;237:536–43.PubMedGoogle Scholar
  48. 48.
    Hanazaki K, Kajikawa S, Shimozawa N, Mihara M, Ko Shimada K, Hiraguri M, et al. Survival and recurrence after hepatic resection of 386 consecutive patients with hepatocellular carcinoma. J Am Coll Surg. 2000;191:381–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2011

Authors and Affiliations

  • Yuko Nagaoki
    • 1
  • Hiroshi Aikata
    • 1
    Email author
  • Daisuke Miyaki
    • 1
  • Eisuke Murakami
    • 1
  • Yoshimasa Hashimoto
    • 1
  • Yoshio Katamura
    • 1
  • Takahiro Azakami
    • 1
  • Tomokazu Kawaoka
    • 1
  • Shintaro Takaki
    • 1
  • Akira Hiramatsu
    • 1
  • Koji Waki
    • 1
  • Michio Imamura
    • 1
  • Yoshiiku Kawakami
    • 1
  • Shoichi Takahashi
    • 1
  • Kazuaki Chayama
    • 1
  1. 1.Programs for Biomedical Research, Division of Frontier Medical Science, Department of Medicine and Molecular Science, Graduate School of Biomedical SciencesHiroshima UniversityHiroshimaJapan

Personalised recommendations